• Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials

Kenneth Ataga, MD

Director, Comprehensive Sickle Cell Program
University of North Carolina, Chapel Hill School of Medicine
Physicians Office Building, 3rd Floor
170 Manning Drive
Chapel Hill, North Carolina, United States

Dr. Ataga’s clinical interest is in classical hematology and hemoglobinopathies. He is the director of the UNC Comprehensive Sickle Cell Program. His clinical research is focused on the vasculopathy of sickle cell disease, with an emphasis on pulmonary hypertension and renal complications, and coagulation activation in sickle cell disease. In addition, Dr. Ataga has a strong research interest in the development of new therapies for sickle cell disease. He conducts clinical trials in sickle cell disease funded by the National Institutes of Health and the Pharmaceutical Industry.


Representative Publications:

Risk factors for mortality in adult patients with sickle cell disease: a meta-analysis of studies in North America and Europe

Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease

Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies

Albuminuria Is Associated with Endothelial Dysfunction and Elevated Plasma Endothelin-1 in Sickle Cell Anemia

Pharmacologic Therapies for Sickle Cell Disease